Dyadic International (DYAI) Scheduled to Post Earnings on Thursday

Dyadic International (NASDAQ:DYAI – Get Rating) will be announcing its earnings results after the market closes on Thursday, May 12th. Analysts expect the company to announce earnings of ($0.09) per share for the quarter. Investors that wish to listen to the company’s conference call can do so using this link.

Dyadic International (NASDAQ:DYAI – Get Rating) last announced its quarterly earnings data on Tuesday, March 29th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.11). The company had revenue of $0.31 million during the quarter, compared to analyst estimates of $5.63 million. Dyadic International had a negative return on equity of 58.65% and a negative net margin of 543.68%. On average, analysts expect Dyadic International to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Shares of Dyadic International stock opened at $2.23 on Thursday. The company’s fifty day simple moving average is $2.99 and its 200-day simple moving average is $3.66. Dyadic International has a 1 year low of $2.10 and a 1 year high of $6.89.

Institutional investors and hedge funds have recently bought and sold shares of the business. Royal Bank of Canada boosted its stake in Dyadic International by 77.9% during the second quarter. Royal Bank of Canada now owns 6,969 shares of the biotechnology company’s stock worth $25,000 after buying an additional 3,051 shares in the last quarter. Morgan Stanley boosted its stake in Dyadic International by 1,167.3% during the second quarter. Morgan Stanley now owns 13,991 shares of the biotechnology company’s stock worth $51,000 after buying an additional 12,887 shares in the last quarter. Dimensional Fund Advisors LP acquired a new stake in Dyadic International during the third quarter worth $68,000. Finally, Millennium Management LLC boosted its stake in Dyadic International by 12.3% during the third quarter. Millennium Management LLC now owns 301,489 shares of the biotechnology company’s stock worth $1,676,000 after buying an additional 33,042 shares in the last quarter. Hedge funds and other institutional investors own 26.12% of the company’s stock.

Separately, HC Wainwright lowered their price objective on shares of Dyadic International from $7.00 to $6.00 and set a “buy” rating on the stock in a research note on Monday, April 4th.

Dyadic International Company Profile (Get Rating)

Dyadic International, Inc, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 platform and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, bi/tri-specific antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins.

Featured Articles